Study to Evaluate the Diagnostic Performance of GEH300079 (68Ga) Injection PET/CT for Detection of PC in Patients With Colorectal, Gastric, Ovarian, or Pancreatic Cancers (PERISCOPE)

← catalyst calendar

NCT07219238 · readout ≤ 1,046 d

Sponsored by GE Healthcare (industry) · GEHC — their whole pipeline →. With Fortrea.

Phase

Phase 2/3

Status

Recruiting

Study type

Interventional

Design

Na · None · Diagnostic

Enrollment

175estimated

Sites

Countries

Sweden, United States

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis

Date

Filed

Basis

What it is

Start

Oct 2026

estimated

When the study began enrolling

Primary completion

Jun 2029

estimated

The date the last participant is measured for the primary outcome — the readout window

Study completion

Aug 2029

estimated

The whole study's end, after follow-up

First posted

2025-10-21

actual

When this record first appeared on the registry

Results posted

—

When the sponsor posted results to the registry

Record updated

2026-06-17

actual

The sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Conditions

Colorectal Cancer
Gastric Cancers
Ovarian Cancers
Pancreatic Ductal Adenocarcinoma

Intervention

Drug: GEH300079 (68Ga) Injection Positron-Emission Tomography (PET)/Computed Tomography (CT)

Primary outcome

what the primary-completion date above is the date OF

Per-region sensitivity and Per-region specificity of GEH300079 (68Ga) PET/CT imaging to detect PC.

measured Single time point. Images will be acquired at 60 minutes ±5 minutes post injection, with a scan duration of approximately 20 to 30 minutes.

Permalink · GEHC's whole pipeline · Catalyst calendar · Every registered study · What changed